It was a slow news day Thursday as our most popular politicians and news pundits were distracted playing Etch-A-Sketch, but a few stories caught my eye...
Robert DiNero has taken a whole lot of slack for his "First Lady" comment, and surprisingly enough for a Hollywood great, he apologized for it.
That doesn't happen every day.
But in all honesty, the guy was just poking a little fun at those who believed that America wasn't ready for Michelle Obama in the White House during the last Presidential campaign. While poking fun, he was also giving her some credit, since she's done a pretty remarkable job moving her own causes forward while staying on the relative sidelines.
The fact that those comments caused so much controversy is just another example of how this country has far lost its sense of humor.
Why's everyone so mad and bitter all the time?
Speaking of mad guys and sense of humors, if the Republican hopefuls have resorted to making Etch-A-Sketch the center of their campaign against the soon-to-be candidate Romney, then it's time to close up shop, go home and watch the final rounds from the same place that the Mets will be watching the playoffs this year - from the couch.
Here's a little message for the Jets - If you want to steal back page headlines, then win a Super Bowl.
Don't steal headlines by begging for a divided locker room and telling the guy that you just signed to a bank deal that the confidence just isn't there.
Tebow isn't close to being a Brett Favre, and how'd that work out for the Gang Green?
Weak move, Jets. Very weak.
In a release by the NY Mets today, it was announced that Mike Pelfrey is pitching with a bum ankle. Two things come to mind - fans are getting fed an excuse as to why he stinks, but more importantly, why is a team who constantly has half of its players on the DL allowing a guy to pitch with a bum ankle?
Let's see what's up in the markets...
NovaBay Pharmaceuticals (NBY): NovaBay shares traded higher for the duration of the day on Thursday on volume more than quadruple the daily norm. Earlier this week the company announced that it would be bringing its technology to the veterinary market in addition to furthering its clinical development in humans.
The market potential of this company's pipeline is very significant should it make to commercialization, given its potential to replace modern day antibiotics, which are quickly becoming irrelevant thanks to over prescribing and resistance.
The boost in volume and price on Thursday could just be a start, if we're considering potential catalysts and eventual market opportunities, especially since a roll-out of NBY's first FDA-approved product, NeutroPhase, is expected to take place this year.
Keep an eye on this one, it could turn into a pivotal year.
Immunocellular Therapeutics (IMUC): Shares of Immunocellular Therapeutics were also flying on Thursday after the company announced that it has added a second major indication to its pipeline of stem-cell attacking cancer immunotherapy treatments.
A late day flurry of activity burst the stock through the three dollar mark to set a new 52-week high.
Developments have been solid all around for IMUC, which has now tripled since the opening days of the year, and a move to the AMEX is widely expected.
The new technology was acquired from the University of Pittsburgh and will be used to create ICT-140 for the treatment of ovarian cancer.
Immunocellular is already developing ICT-107 for the treatment of glioblastoma.
Implant Sciences (IMSC): Implant Sciences spiked by ten percent on Thursday on volume nearly four times the expected norm. On Wednesday the company announced that it had received a patent from the US Patent and Trademark Office covering the methods behind its Narcotics and Explosives Particle Removal System.
Investors liked the news of the broadening scope of intellectual property protection that the company is receiving for its technology, and shares reacted as a result.
It's likely that all this one needs to breach a dollar again is some significant headway into the US Homeland Security market.
Galena Biopharma (GALE): Galena made many a stock market watch list yesterday after having run very significantly and rapidly on positive patent news earlier in the week. Volume was up, shares were running, and Thursday opened with the same momentum - until a late day dose of reality came thundering down with huge volume leading into the close.
Runs like this one in the biotech and small pharmaceutical sectors can help investors realize significant gains, but the GALE run is another example of why it's best to have a few trading shares on hands in order to turn those paper gains into realized gains.
Although the long term potential may still be there, why not guarantee a couple of Goose martinis on house money?
CytRx Corporation (CYTR) had a late day volume surge that resulted in a close 8% higher than the opening prices...Celsius Holdings (CELH) remains trading with higher than usual volume, but most of the volume is coming at around thirty cents, although the closing prices are much higher, in terms of percentages... and as predicted yesterday, shares of FuelCell (FCEL) dropped by over ten percent on a financing announcement.
Disclosure: Long IMUC, NBY, IMSC, CELH.
Contact VFC's Stock House: email@example.com
Originally published at: http://vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213